VBI Vaccines Inc.
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vacci… Read more
VBI Vaccines Inc. (VBIVQ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2024: 2.153x
Based on the latest financial reports, VBI Vaccines Inc. (VBIVQ) has a cash flow conversion efficiency ratio of 2.153x as of March 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.77 Million) by net assets ($-5.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
VBI Vaccines Inc. - Cash Flow Conversion Efficiency Trend (2020–2023)
This chart illustrates how VBI Vaccines Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
VBI Vaccines Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VBI Vaccines Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SPO Global Inc
PINK:SPOM
|
-0.168x |
|
American Oriental Bioengineering Inc
PINK:AOBI
|
-0.060x |
|
Environmental Solutions Worldwide Inc
PINK:ESWW
|
0.014x |
|
Itokk Inc
PINK:IKTO
|
0.203x |
|
Xalles Holdings Inc
PINK:XALL
|
0.010x |
|
Gold And Gemstone
PINK:GGSM
|
0.013x |
|
Cableclix USA Inc
PINK:CCLX
|
0.019x |
|
GEROVA Financial Group Ltd
PINK:GVFG
|
0.010x |
Annual Cash Flow Conversion Efficiency for VBI Vaccines Inc. (2020–2023)
The table below shows the annual cash flow conversion efficiency of VBI Vaccines Inc. from 2020 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $7.53 Million | $-60.88 Million | -8.089x | -604.24% |
| 2022-12-31 | $64.16 Million | $-73.69 Million | -1.149x | -314.09% |
| 2021-12-31 | $143.88 Million | $-39.91 Million | -0.277x | -1.22% |
| 2020-12-31 | $171.71 Million | $-47.05 Million | -0.274x | -- |